読み込み中
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.
前日終値
$3.2186
+$0.0386 · +1.21%
日中の時刻はETです。市場データは遅延する場合があります。
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.
日中レンジ
現在 $3.2186
52週レンジ
現在 $3.2186
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
強い売り
バリュエーション
2
著しい割高
センチメント
45
まちまち
リスク
82
極めて高いリスク
モメンタム
31
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.
日中レンジ
現在 $3.2186
52週レンジ
現在 $3.2186
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（CHF） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 3万 CHF | 40.41万 CHF | 161.3万 CHF | 142.24万 CHF | 291.63万 CHF |
| 粗利益 | 3万 CHF | 40.41万 CHF | 161.3万 CHF | 142.24万 CHF | 291.63万 CHF |
| 研究開発 | 19.02万 CHF | 43.52万 CHF | 94.27万 CHF | 788.35万 CHF | 901.41万 CHF |
| 販売・一般管理 | 188.79万 CHF | 167.52万 CHF | 203.1万 CHF | 326.2万 CHF | 774.63万 CHF |
| 営業費用 | 284.46万 CHF | 315.93万 CHF | 385.59万 CHF | 1196.33万 CHF | 1842.22万 CHF |
| 受取利息 | — | 9165 CHF | 6.4万 CHF | 2.93万 CHF | 5322 CHF |
| 支払利息 | 2421 CHF | 3547 CHF | 2.16万 CHF | 4.89万 CHF | 6.3万 CHF |
| 減価償却費と償却費 | 8472 CHF | 26.01万 CHF | 30.6万 CHF | 32.31万 CHF | 34.76万 CHF |
| 営業利益 | −281.46万 CHF | −275.52万 CHF | −224.3万 CHF | −1054.09万 CHF | −1550.59万 CHF |
| 純利益 | −672.82万 CHF | 705.58万 CHF | −1055.62万 CHF | −2080.42万 CHF | −1535.19万 CHF |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
